Answers are grounded in this paper and cite their sources.
Background DENND2D, a key member of the DENND2 family, plays a significant role in the pathogenesis and progression of various diseases, including high-grade gliomas, colon cancer, bladder cancer, and sepsis. However, its function in low-grade gliomas (LGG) remains unclear. Methods This study comprehensively assessed the expression differences and prognostic value of DENND2D across various tumors using the Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and Genotype-Tissue Expression (GTEx) databases. A further integrated analysis was then conducted to evaluate the association of DENND2D expression with clinical features, prognosis, biological functions, immune microenvironment, and genetic alterations in LGG. Concurrently, in vitro and in vivo experiments were performed to investigate the specific role of DENND2D in LGG. Results DENND2D expression is significantly upregulated in the majority of tumors and shows a strong correlation with poor prognosis in LGG, serving as an independent prognostic biomarker for LGG patients. Its expression in LGG is closely associated with immune checkpoint genes (ICGs), the immune microenvironment, M2 macrophage infiltration, and tumor mutational burden. Functional assays demonstrated that DENND2D is critically involved in regulating cell viability, proliferation, and migration, thereby promoting tumor progression both in vitro and in vivo . Conclusion DENND2D is an important factor influencing the clinical prognosis of LGG patients and a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Xiaolong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: